CT
The startup develops microRNA-based therapies that target the molecular mechanisms leading to tendinopathy in musculoskeletal diseases. By mimicking natural microRNA, their treatments facilitate tendon repair and significantly reduce pain associated with damaged tendons.
Updated 18 months ago
Funding
$19.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DD
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops microRNA-based therapies that target the molecular mechanisms leading to tendinopathy in musculoskeletal diseases. By mimicking natural microRNA, their treatments facilitate tendon repair and significantly reduce pain associated with damaged tendons.